Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Loss of smooth muscle CYB5R3 amplifies angiotensin II–induced hypertension by increasing sGC heme oxidation
Brittany G. Durgin, … , Peter Sandner, Adam C. Straub
Brittany G. Durgin, … , Peter Sandner, Adam C. Straub
Published September 5, 2019
Citation Information: JCI Insight. 2019;4(19):e129183. https://doi.org/10.1172/jci.insight.129183.
View: Text | PDF
Research Article Vascular biology

Loss of smooth muscle CYB5R3 amplifies angiotensin II–induced hypertension by increasing sGC heme oxidation

  • Text
  • PDF
Abstract

Nitric oxide regulates BP by binding the reduced heme iron (Fe2+) in soluble guanylyl cyclase (sGC) and relaxing vascular smooth muscle cells (SMCs). We previously showed that sGC heme iron reduction (Fe3+ → Fe2+) is modulated by cytochrome b5 reductase 3 (CYB5R3). However, the in vivo role of SMC CYB5R3 in BP regulation remains elusive. Here, we generated conditional smooth muscle cell–specific Cyb5r3 KO mice (SMC CYB5R3–KO) to test if SMC CYB5R3 loss affects systemic BP in normotension and hypertension via regulation of the sGC redox state. SMC CYB5R3–KO mice exhibited a 5.84-mmHg increase in BP and impaired acetylcholine-induced vasodilation in mesenteric arteries compared with controls. To drive sGC oxidation and elevate BP, we infused mice with angiotensin II. We found that SMC CYB5R3–KO mice exhibited a 14.75-mmHg BP increase, and mesenteric arteries had diminished nitric oxide–dependent vasodilation but increased responsiveness to sGC heme-independent activator BAY 58-2667 over controls. Furthermore, acute injection of BAY 58-2667 in angiotensin II–treated SMC CYB5R3–KO mice showed greater BP reduction compared with controls. Together, these data provide the first in vivo evidence to our knowledge that SMC CYB5R3 is an sGC heme reductase in resistance arteries and provides resilience against systemic hypertension development.

Authors

Brittany G. Durgin, Scott A. Hahn, Heidi M. Schmidt, Megan P. Miller, Neha Hafeez, Ilka Mathar, Daniel Freitag, Peter Sandner, Adam C. Straub

×

Figure 1

SMC CYB5R3–KO mice have a significantly elevated MAP and reduced heart rate compared with WT mice under physiological conditions.

Options: View larger image (or click on image) Download as PowerPoint
SMC CYB5R3–KO mice have a significantly elevated MAP and reduced heart r...
(A) The experimental design where WT (n = 10, gray) and SMC CYB5R3–KO (n = 10, red) mice after tamoxifen treatment were implanted with telemetry units and BP monitored continuously for 24 hours. (B) SMC CYB5R3–KO mice have a significantly increased MAP compared with WT mice. (C) SMC CYB5R3–KO mice have a significantly decreased heart rate compared with WT mice. (B and C) P values represent significant differences between WT and SMC CYB5R3–KO by 2-way repeated- measures ANOVA with *P < 0.05 by Sidak multiple comparison tests. Error bars represent ± SEM.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts